Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
- Resource Type
- Article
- Source
- The Lancet HIV; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 24054704; 23523018